bristoldrv Posted February 28, 2019 Report Share Posted February 28, 2019 Big investors are lining up to oppose Bristol-Myers Squibb's buyout of Celgene AxiosHedge funds Wellington Management and Starboard Value both oppose Bristol-Myers Squibb's $74 billion takeover of Celgene. Starboard said in an open letter ... View the full article Quote Link to comment Share on other sites More sharing options...